- Conditions
- Ulcerative Colitis, Crohn's Disease
- Interventions
- Vedolizumab IV, Vedolizumab SC
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 101
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 89 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–80
of 80
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Small Bowel Crohn's Disease
- Interventions
- Not listed
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Colitis, Ulcerative
- Interventions
- Vedolizumab IV
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 278 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 44
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • San Pablo, California + 40 more
- Conditions
- Immune Checkpoint Inhibitor-Related Colitis
- Interventions
- Vedolizumab 300 MG Injection [Entyvio], Prednisone (and methylprednisolone), Prednisone Taper, Placebo Prednisone Capsules, Placebo Vedolizumab, Sulfamethoxazole-Trimethoprim, Placebo for Sulfamethoxazole-Trimethoprim
- Drug · Other
- Lead sponsor
- Shilpa Grover, MD, MPH
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Type 1 Diabetes
- Interventions
- Etanercept, Vedolizumab
- Drug
- Lead sponsor
- Benaroya Research Institute
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 2
- States / cities
- La Jolla, California • Seattle, Washington
- Conditions
- Healthy Volunteers
- Interventions
- Vedolizumab SC
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Colitis, Ulcerative
- Interventions
- Vedolizumab 300 mg IV, Placebo IV, Vedolizumab 108 mg SC, Placebo SC
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 383 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 28
- States / cities
- Little Rock, Arkansas • Wheat Ridge, Colorado • Middletown, Connecticut + 25 more
- Conditions
- Ulcerative Colitis
- Interventions
- Risankizumab, Vedolizumab
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 573 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 65 more